Literature DB >> 19771361

Decavanadate interactions with actin: cysteine oxidation and vanadyl formation.

Susana Ramos1, Rui O Duarte, José J G Moura, Manuel Aureliano.   

Abstract

Incubation of actin with decavanadate induces cysteine oxidation and oxidovanadium(IV) formation. The studies were performed combining kinetic with spectroscopic (NMR and EPR) methodologies. Although decavanadate is converted to labile oxovanadates, the rate of deoligomerization can be very slow (half-life time of 5.4 h, at 25 degrees C, with a first order kinetics), which effectively allows decavanadate to exist for some time under experimental conditions. It was observed that decavanadate inhibits F-actin-stimulated myosin ATPase activity with an IC(50) of 0.8 microM V(10) species, whereas 50 microM of vanadate or oxidovanadium(IV) only inhibits enzyme activity up to 25%. Moreover, from these three vanadium forms, only decavanadate induces the oxidation of the so called "fast" cysteines (or exposed cysteine, Cys-374) when the enzyme is in the polymerized and active form, F-actin, with an IC(50) of 1 microM V(10) species. Decavanadate exposition to F- and G-actin (monomeric form) promotes vanadate reduction since a typical EPR oxidovanadium(IV) spectrum was observed. Upon observation that V(10) reduces to oxidovanadium(IV), it is proposed that this cation interacts with G-actin (K(d) of 7.48 +/- 1.11 microM), and with F-actin (K(d) = 43.05 +/- 5.34 microM) with 1:1 and 4:1 stoichiometries, respectively, as observed by EPR upon protein titration with oxidovanadium(IV). The interaction of oxidovanadium(IV) with the protein may occur close to the ATP binding site of actin, eventually with lysine-336 and 3 water molecules.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19771361     DOI: 10.1039/b906255f

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  5 in total

1.  Recent perspectives into biochemistry of decavanadate.

Authors:  Manuel Aureliano
Journal:  World J Biol Chem       Date:  2011-10-26

2.  Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B.

Authors:  Thomas Scior; José Antonio Guevara-García; F J Melendez; Hassan H Abdallah; Quoc-Tuan Do; Philippe Bernard
Journal:  Drug Des Devel Ther       Date:  2010-09-24       Impact factor: 4.162

Review 3.  Decavanadate Toxicology and Pharmacological Activities: V10 or V1, Both or None?

Authors:  M Aureliano
Journal:  Oxid Med Cell Longev       Date:  2016-01-21       Impact factor: 6.543

4.  Rationalizing the Decavanadate(V) and Oxidovanadium(IV) Binding to G-Actin and the Competition with Decaniobate(V) and ATP.

Authors:  Giuseppe Sciortino; Manuel Aureliano; Eugenio Garribba
Journal:  Inorg Chem       Date:  2020-11-30       Impact factor: 5.165

5.  Cytotoxicity and enzyme inhibition studies of polyoxometalates and their chitosan nanoassemblies.

Authors:  Hamid Saeed Shah; Rami Al-Oweini; Ali Haider; Ulrich Kortz; Jamshed Iqbal
Journal:  Toxicol Rep       Date:  2014-06-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.